Longeveron (LGVN) Revenue Growth (1y) (2021 - 2026)
Longeveron (LGVN) Revenue Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.45% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 16.73% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 29.63% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 66.86% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -99.97% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 296.11% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 16.50% |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -9.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.18% |
| Mar 31, 2026 | 4.46% |
| Dec 31, 2025 | -39.47% |
| Sep 30, 2025 | -82.28% |
| Jun 30, 2025 | -32.48% |
| Mar 31, 2025 | -30.47% |
| Dec 31, 2024 | 857.14% |
| Sep 30, 2024 | 415.33% |
| Jun 30, 2024 | 115.67% |
| Mar 31, 2024 | 96.42% |
| Dec 31, 2023 | -47.93% |
| Sep 30, 2023 | 50.00% |
| Jun 30, 2023 | -53.43% |
| Mar 31, 2023 | -10.00% |
| Dec 31, 2022 | -42.11% |
| Sep 30, 2022 | -56.90% |
| Jun 30, 2022 | -4.70% |
| Mar 31, 2022 | -17.55% |
| Sep 30, 2021 | -87.56% |
| Jun 30, 2021 | 63.00% |